Global Vanishing Bone Disease Market Research Report: Diagnosis (X-Rays, CT Scans, MRIs, Ultrasound, Nuclear Medicine, Others), Treatment (Medicine Therapy, Radiation Therapy), End-User (Hospitals, Diagnostic Centers, Others) – Global Forecast Till 2023

Market Scenario
The global vanishing bone disease market size is expected to gain prominence over the forecast period (2018–2023). It is estimated that the global vanishing bone disease industry is expected to register a CAGR ~6.1 % during the forecast period of 2018–2023.

Vanishing bone disease or Gorham-stout syndrome is a rare skeletal disease characterized by progressive osteolysis and the proliferation of lymphatic vessels within the bone which leads to the destruction and absorption of bone. Additionally, the bones affected by the disease are more prone to osteopenia and fracture. Furthermore, the exact cause of the disease is unknown. However, it is considered to be caused due to the improper development of the lymphatic system.

According to the National Center for Advancing Translational Sciences (NIH), in 2016, the number of cases of vanishing bone disease reported ranged from 64 to 200 cases globally. The growing occurrence of the disease is the key driver for the growth of the market. Furthermore, current research for the development of the effective therapeutic intervention for the disease treatment is expected to contribute to the growth of the market.

However, lack of awareness of the disease in developing economies, high treatment cost restrains the market growth. Furthermore, challenges in diagnosis of the disease in the patient pool may hamper the growth of the market.

Segmentation
The global vanishing bone disease market is segmented on the basis of the diagnosis, treatment, and end-user.

On the basis of diagnosis, the market is classified as X-rays, CT scans, MRIs, ultrasound, nuclear medicine, and others.

The global vanishing bone disease market on the basis of treatment is segmented as medical therapy and radiation therapy. The medicine therapy is segmented into bisphosphonates, vitamin D, interferon, a-2b interferon, calcium, adrenal extracts, androgen, bleomycin, and others. The radiation therapy is further segmented into chest drainage, thoracic duct ligation, pleurodesis, pleurectomy, and others.

On the basis of end-user, the global vanishing bone disease market is segmented as hospitals & clinics, diagnostic centers, ambulatory surgical centers, and others.

Geographically, the global vanishing bone disease market has been segmented into America, Europe, Asia Pacific, and the Middle East and Africa. The American vanishing bone disease market is further segmented into North America and South America. North America is further classified as the U.S. and Canada.

The European vanishing bone disease market is segmented into Western Europe and Eastern Europe. Western Europe is further classified as Germany, France, the U.K., Italy, Spain, and
the rest of Western Europe.

The Asia Pacific, vanishing bone disease market, is segmented into Japan, China, India, Republic of Korea, Australia, and the rest of Asia Pacific.

The Middle Eastern and African vanishing bone disease market is segmented into the Middle East and Africa.

Regional Market Summary

Global Vanishing Bone Disease Market, by Region Market Share, 2017 (%)

Source: MRFR Analysis

The global vanishing bone disease market consists of four regions: Americas, Europe, Asia Pacific and the Middle East & Africa. The North American region dominates the global vanishing bone market due to the existing well-established healthcare system, increasing occurrences of rare diseases. For instance, according to the National Institute of Health, rare disorders that affect approximately 30 million people in the United States. Furthermore, according to the U.S. FDA, rare diseases or disorder affects an approximate 200,000 people in the United States.

Europe holds the second market share in the global vanishing bone disease market. It is expected that the government support towards research & development expenditure and rising incidences of rare diseases is likely to drive the European vanishing bone disease market. For instance, according to the European Commission, rare diseases comprises 5000 to 8000 life-threatening or chronically debilitating diseases which together affect from 27 and 36 million people in the European Union.

The Asia Pacific, vanishing bone disease market, consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia Pacific. The market growth in this region is driven by rising healthcare expenditure, rising occurrences of rare diseases, and growing bone disorders, technological advancements in interventional radiology segment. For instance, in February 2018, Elekta AB received clearance from China Food and Drug Administration (CFDA) for its Leksell Gamma Knife Icon radiosurgery system.

The Middle East & Africa holds the lowest share of the global vanishing bone disease market due to lack of awareness of rare diseases, the low incidence rate of the disease and poor medical facilities, especially in the African region.

Key Players

Varian Medical Systems, Inc., Elekta AB, C. R. Bard, Inc., Teleflex Incorporated, Vygon S.A. Medtronic plc., Cook Medical, Smiths Medical, ATMOS MedizinTechnik GmbH & Co. KG, Merck & Co., Sanofi-Aventis, F. Hoffmann-La Roche AG, and Novartis International AG are some prominent players in this market.

Research Methodology

Market Research Future research is conducted by industry experts who offer insight into industry structure, market segmentation, Treatment assessment, competitive landscape (CL), penetration, as well as on emerging trends. Besides primary interviews (~ 80%) and secondary research (~ 20%), their analysis is based on their years of professional expertise in respective industries. Our analysts also predict where the market will be headed in the next five to ten years, by analyzing historical trends and current market positions. Furthermore, the varying trends of segments & categories geographically presented are studied and are estimated based on primary & secondary research.
• **Primary Research**

The extensive primary research was conducted to gain a deeper insight into the market and the industry performance. In this particular report, we have conducted primary surveys (interviews) with the key level executives (VPs, CEOs, Marketing Directors, Business Development Managers, and many more) of the major players who are active in the market. In addition to analyzing the current and historical trends, our analysts predict where the market is headed, over the next five to ten years.

• **Secondary Research**

Secondary research was mainly used to collect and identify information useful for an extensive, technical, market-oriented, and commercial study of the vanishing bone disease market. It was also used to obtain key information about major players, market classification and segmentation according to the industry trends, geographical markets, & developments related to the market and Treatment Perspectives. For this study, analysts have gathered information from various credible sources, such as annual reports, SEC filings, journals, white papers, corporate presentations, company websites, the international organization of chemical manufacturers, some paid databases and many others.

**Global Vanishing Bone Disease Market, by Diagnosis**

- X-rays
- CT Scans
- MRIs
- Ultrasound
- Nuclear Medicine
- Others

**Global Vanishing Bone Disease Market, by Treatment**

- Medicine Therapy
- Bisphosphonates
- Vitamin D
- Interferon
- α-2b Interferon
- Calcium
- Adrenal extracts
- Androgens
- Bleomycin
- Others
- Radiation Therapy
- Chest drainage
- Thoracic Duct Ligation
- Pleurodesis
- Pleurectomy
- Others

**Global Vanishing Bone Disease Market, by End-User**

- Hospitals and clinics
- Diagnostic centers
- Ambulatory surgical centers

**Global Vanishing Bone Disease Market, by Region**

- Americas
- North America
- U.S.
- Canada
- South America
- Europe
- Western Europe
- Germany
- France
- Italy
- Spain
- U.K.
Rest of Western Europe
Eastern Europe
Asia Pacific
Japan
China
India
Australia
Republic of Korea
Rest of Asia Pacific
The Middle East & Africa
Middle East
Africa

Intended Audience

- Pharmaceutical Companies
- Research and Development (R&D) Companies
- Government Research Institutes

Contents:

Table of Contents:

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis

Chapter 6. Global Vanishing Bone Disease Market, by Diagnosis

6.1 Introduction
6.2 X-ray
Market Estimates & Forecast, by Region, 2018–2023
6.3 CT Scans
Market Estimates & Forecast, by Region, 2018–2023
6.4 MRIs
Market Estimates & Forecast, by Region, 2018–2023
6.5 Ultrasound
Market Estimates & Forecast, by Region, 2018–2023
6.6 Nuclear Medicine
Market Estimates & Forecast, by Region, 2018–2023
6.7 Others

Chapter 7. Global Vanishing Bone Disease Market, by Treatment
7.1 Introduction
7.2 Medicine Therapy
7.2.1 Bisphosphonates
Market Estimates & Forecast, by Region, 2018–2023
7.2.2 Vitamin D
Market Estimates & Forecast, by Region, 2018–2023
7.2.3 Interferon
Market Estimates & Forecast, by Region, 2018–2023
7.2.4 a-2b Interferon
Market Estimates & Forecast, by Region, 2018–2023
7.2.5 Calcium
Market Estimates & Forecast, by Region, 2018–2023
7.2.6 Adrenal Extracts
Market Estimates & Forecast, by Region, 2018–2023
7.2.7 Androgens
Market Estimates & Forecast, by Region, 2018–2023
7.2.8 Bleomycin
Market Estimates & Forecast, by Region, 2018–2023
7.2.9 Others
7.3 Radiation Therapy
7.3.1 Chest Drainage
Market Estimates & Forecast, by Region, 2018–2023
7.3.2 Thoracic Duct Ligation
Market Estimates & Forecast, by Region, 2018–2023

7.3.3 Pleurodesis
Market Estimates & Forecast, by Region, 2018–2023

7.3.4 Pleurectomy
Market Estimates & Forecast, by Region, 2018–2023

7.3.5 Others

Chapter 8. Global Vanishing Bone Disease Market, by End-User
8.1 Introduction

8.2 Hospitals & clinics
Market Estimates & Forecast, by Region, 2018–2023

8.3 Diagnostic Centers
Market Estimates & Forecast, by Region, 2018–2023

8.4 Ambulatory Surgical Centers
Market Estimates & Forecast, by Region, 2018–2023

8.4 Others

Chapter 9. Global Vanishing Bone Disease Market, by Region
9.1 Introduction

9.2 Americas
9.2.1 North America
9.2.1.1 U.S.
9.2.1.2 Canada
9.2.2 South America

9.3 Europe
9.3.1 Western Europe
9.3.1.1 Germany
9.3.1.2 France
9.3.1.3 Italy
9.3.1.4 Spain
9.3.1.5 U.K.
9.3.1.6 Rest of Western Europe
9.3.2 Eastern Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 Republic of Korea
9.4.6 Rest of Asia Pacific
9.5 The Middle East & Africa
9.5.1 The Middle East
9.5.2 Africa
Chapter 10. Company Landscape

10.1 Introduction
10.2 Market Share Analysis
10.3 Key Development & Strategies

Chapter 11. Company Profiles

11.1 Varian Medical Systems, Inc.
11.1.1 Company Overview
11.1.2 Product Overview
11.1.3 Financials Overview
11.1.4 Key Developments
11.1.5 SWOT Analysis

11.2 Elekta AB
11.2.1 Company Overview
11.2.2 Product Overview
11.2.3 Financial Overview
11.2.4 Key Developments
11.2.5 SWOT Analysis

11.3 C.R. Bard, Inc.
11.3.1 Company Overview
11.3.2 Product Overview
11.3.3 Financials Overview
11.3.4 Key Development
11.3.5 SWOT Analysis

11.4 Teleflex Incorporated
11.4.1 Company Overview
11.4.2 Technology/Business Segment Overview
11.4.3 Financial Overview
11.4.4 Key Development
11.4.5 SWOT Analysis

11.5 Vygon S.A.
11.5.1 Company Overview
11.5.2 Product Overview
11.5.3 Financial overview
11.5.4 Key Developments
11.5.5 SWOT Analysis

11.6 Medtronic Plc
11.6.1 Company Overview
11.6.2 Product Overview
11.6.3 Financial Overview
11.6.4 Key Developments
11.6.5 SWOT Analysis

11.7 Cook Medical
11.7.1 Overview
11.7.2 Product Overview
11.7.3 Financial Overview
11.7.4 Key Developments
11.7.5 SWOT Analysis

11.8 Smiths Medical
11.8.1 Overview
11.8.2 Product/ Technology Overview
11.8.3 Financials
11.8.4 Key Developments
11.8.5 SWOT Analysis

11.9 ATMOS Medizin Technik GmbH & Co. KG
11.9.1 Overview
11.9.2 Product Overview
11.9.3 Financials
11.9.4 Key Developments
11.9.5 SWOT Analysis

11.10 Merck & Co.
11.10.1 Overview
11.10.2 Product Overview
11.10.3 Financials
11.10.4 Key Developments
11.10.5 SWOT Analysis

11.11 Sanofi-Aventis
11.11.1 Overview
11.11.2 Product Overview
11.11.3 Financials
11.11.4 Key Developments
11.11.5 SWOT Analysis

11.12 F. Hoffman-La Roche AG
11.12.1 Overview
11.12.2 Product Overview
11.12.3 Financials
11.12.4 Key Developments
11.12.5 SWOT Analysis

11.13 Novartis International AG
11.13.1 Overview
11.13.2 Product Overview
11.13.3 Financials
11.13.4 Key Developments
11.13.5 SWOT Analysis

Chapter 12 MRFR Conclusion
12.1 Key Findings
12.1.1 From CEO’s View Point
12.1.2 Unmet Needs of the Market
12.2 Key Companies to Watch
12.3 Prediction of the Arthroscopy Instruments Industry

Chapter 13 Appendix

LIST OF TABLES
Table 1 Global Vanishing Bone Disease Market Synopsis, 2018–2023
Table 2 Global Vanishing Bone Disease Market Estimates and Forecast, 2018–2023, (USD Million)
Table 3 Global Vanishing Bone Disease Market, by Region, 2018–2023, (USD Million)
Table 4 Global Vanishing Bone Disease Market, by Diagnosis, 2018–2023, (USD Million)
Table 5 Global Vanishing Bone Disease Market, by Treatment, 2018–2023, (USD Million)